fda warning letters compounded semaglutide october 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of GLP-1 Drugs and Telehealth Providers FDA warns consumers not to

Mazdutide is based on oxyntomodulin, a natural hormone released from your intestines after eating

Description RETATRUTIDE PEN 20MG 20mg retatrutide mixed with 2ml of hospira bacteriostatic water Important Note on Vial Fill Level Our research vials have a total capacity of 3ml

The FDA does not recommend using medications beyond their labeled expiration dates, as potency cannot be guaranteed and therapeutic goals may not be achieved

The most common adverse events were gastrointestinal, and most were mild to moderate

Concerns about lean mass loss and metabolism Clinical data shows semaglutide can reduce lean body mass, with losses ranging from nearly 0% to 40% of total weight reduction

Given the widespread use of these medications for metabolic diseases, clinicians and researchers are now examining how they impact the brain particularly regarding mood, depression, and addictive behaviors